NCT01526733View on ClinicalTrials.gov

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2013

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Sham Injection

DRUG

Recombinant human hyaluronidase PH20

DRUG

Insulin aspart

DRUG

Insulin lispro

Trial Locations (1)

91911

Profil Institute for Clinical Research, Chula Vista

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT01526733 - Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase | Biotech Hunter | Biotech Hunter